|
[1]
|
Campbell, K., Pustover, K. and Morgan, M.B. (2016) Merkel Cell Carcinoma. In: Crowe, D., Morgan, M., Somach, S. and Trapp, K., Eds., Deadly Dermatologic Diseases: Clinicopathologic Atlas and Text, Springer International Publishing, Berlin, 41-46. [Google Scholar] [CrossRef]
|
|
[2]
|
Lemos, B.D., Storer, B.E., Iyer, J.G., et al. (2010) Pathologic Nodal Evaluation Improves Prognostic Accuracy in Merkel Cell Carcinoma: Analysis of 5823 Cases as the Basis of the First Consensus Staging System. Journal of the American Academy of Dermatology, 63, 751-761. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Bhatia, S., Afanasiev, O. and Nghiem, P. (2011) Immunobiology of Merkel Cell Carcinoma: Implications for Immunotherapy of a Polyomavirus-Associated Cancer. Current Oncology Reports, 13, 488-497. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Cassler, N.M., Merrill, D., Bichakjian, C.K., et al. (2016) Merkel Cell Carcinoma Therapeutic Update. Current Treatment Options in Oncology, 17, 36. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Feng, H., Shu-da, M., Chang, Y., et al. (2008) Clonal Integration of a Poly-Omavirus in Human Merkel Cell Carcinoma. Science, 319, 1096-1100. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Esther, S.K. (2017) Avelumab: First Global Approval.
|
|
[7]
|
Kaufman, H.L., Russell, J., Hamid, O., et al. (2016) Avelumab in Patients with Chemotherapy-Refractory Metastatic Merkel Cell Carcinoma: A Multicentre, Sin-gle-Group, Open-Label, Phase 2 Trial. The Lancet Oncology, 17, 1374-1385. [Google Scholar] [CrossRef]
|
|
[8]
|
EMD Serono Inc. and Pfizer Inc. (2017) Bavencio® (avelumab) Injection: US Prescribing Information.
|
|
[9]
|
US FDA (2017) FDA Approves First Treatment for Rare Form of Skin Cancer. https://www.fda.gov
|
|
[10]
|
EMD Serono (2017) EMD Serono—About Us. http://www.emdserono.com
|
|
[11]
|
Pfizer (2016) European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Car-cinoma [Media Release]. http://www.pfizer.com
|
|
[12]
|
Adis Insight (2017) Drug Profile: Avelumab. http://adisinsight.springer.com
|
|
[13]
|
Merck KGaA (2014) Announces Global Strategic Alliance with Pfizer on Anti-PD-L1 to Acceler-ate Presence in Immuno-Oncology. http://www.businesswire.com
|
|
[14]
|
Pfizer (2014) Pfizer Forms Global Strategic Alliance with Merck KGaA, Germany, to Jointly Develop and Commercialize Anti-PD-L1 to Accelerate Presence in Immuno-Oncology [Media Re-lease]. http://www.pfizer.com
|
|
[15]
|
Pfizer (2016) Merck KGaA, Darmstadt, Germany, Pfizer and Syndax Announce Collaboration to Evaluate Combination of Avelumab and Entinostat in Ovarian Cancer [Media Release]. http://www.pfizer.com
|
|
[16]
|
Boyerinas, B., Jochems, C., Fantini, M., et al. (2015) Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunology Research, 3, 1148-1157. [Google Scholar] [CrossRef]
|
|
[17]
|
Fujii, R., Friedman, E.R., Richards, J., et al. (2016) Enhanced Killing of Chor-doma Cells by Antibody-Dependent Cell-Mediated Cytotoxicity Employing the Novel Anti-PD-L1 Antibody Avelumab. Oncotarget, 7, 33498-33511. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
European Medicines Agency (2017) European Public Assessment Report: Bavencio (Avelumab).
http://www.ema.europa.eu
|
|
[19]
|
Heery, C.R., O’Sullivan-Coyne, G., Madan, R.A., et al. (2017) Avelumab for Metastatic or Locally Advanced Previously Treated Solid Tumours (JAVELIN Solid Tumor, a Phase 1a, Multicohort, Dose-Escalation Trial. The Lancet Oncology, 18, 587-598.
|
|
[20]
|
European Medicines Agency (2018) Bavencio (Avelumab, Summary of Product Characteristics).
http://www.ema.europa.eu
|
|
[21]
|
Pfizer (2016) Merck, Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer [Media Release]. http://www.pfizer.com
|
|
[22]
|
Pfizer (2015) Avelumab Fact Sheet. https://www.pfizer.com
|
|
[23]
|
Heery, C.R., O’Sullivan-Coyne, G., Madan, R.A., et al. (2017) Avelumab for Metastatic or Locally Ad-vanced Previously Treated Solid Tumours (JAVELIN Solid Tumor, a Phase 1a, Multicohort, Doseescalation Trial. The Lancet Oncol-ogy, 45, 39. [Google Scholar] [CrossRef]
|
|
[24]
|
Grenga, I., Donahue, R.N., Lepone, L.M., et al. (2016) A Fully Human IgG1 Anti-PD-L1 MAb in an in Vitro Assay Enhances Antigen-Specific T-Cell Responses. Clinical & Translational Immu-nology, 5, e83. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Transgene (2016) Transgene Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate the Combination of TG4001 with Avelumab in HPV-Positive Head and Neck Cancer in a Phase 1/2 Study [Media Release]. http://www.transgene.fr
|
|
[26]
|
Vaccinex (2016) Vaccinex Announces Clinical Collaboration with Merck KGaA, Darmstadt, Germany, to Evaluate the Combination of VX15/2503, and Avelumab in Non-Small Cell Lung Cancer [Media Release].
http://www.vaccinex.com
|
|
[27]
|
Pfizer (2016) Pfizer to Collaborate with National Cancer Institute to Study Three Immunotherapy Agents Targeting Multiple Cancers [Media Release]. http://www.pfizer.com
|
|
[28]
|
Debiopharm (2016) Debiopharm International SA Announces Clinical Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer in Cancer Immunotherapy [Media Release].
https://www.debiopharm.com
|
|
[29]
|
Pfizer (2017) FDA Grants Approval for BAVENCIO®(Avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma [Media Release]. http://www.pfizer.com
|
|
[30]
|
Kelly, K., Heery, C.R., Patel, M.R., et al. (2016) Avelumab (MSB0010718C; anti-PD-L1) in Patients with Advanced Cancer: Safety Data from 1300 Patients Enrolled in the Phase 1b JAVELIN Solid Tumor Trial. Journal of Clinical Oncology, 34, 3055-3055.
|
|
[31]
|
Gulley, J.L., Rajan, A., Spigel, D.R., et al. (2017) Avelumab for Patients with Previously Treated Metastatic or Recurrent Non-Small-Cell Lung Cancer (JAVELIN Solid Tumor, Dose-Expansion Cohort of a Multicentre, Open-Label, Phase 1b Trial. The Lancet Oncology, 52, 323-329. [Google Scholar] [CrossRef]
|
|
[32]
|
U.S. (2017) Food and Drug Administration. Avelumab (BAVENCIO).
https://www.fda.gov
|
|
[33]
|
Verschraegen, C.F., Chen, F., Spigel, D.R., et al. (2016) Avelumab (MSB0010718C; anti-PD-L1) as a First-Line Treatment for Patients with Advanced NSCLC from the JAVELIN Solid Tumor Phase 1b Trial: Safety, Clinical Activity, and PD-L1 Expression. Journal of Clinical Oncology, 34, 9036-9036.
|
|
[34]
|
US FDA (2017) Bavencio®Avelumab, US Prescribing Infor-mation. http://www.fda.gov
|
|
[35]
|
D’Angelo, S.P., Russell, J., Lebbe, C., et al. (2018) Efficacy and Safety of First-Line Avelumab Treatment in Patients with Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial. JAMA On-cology, 4, e180077. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
D’Angelo, S.P., Russell, J.S., Bhatia, S., et al. (2018) 18-Month Efficacy and Safety Update from JAVELIN Merkel 200 Part A: A Phase II Study of Avelumab in Metastatic Merkel Cell Carcinoma Progressed Onchemotherapy [Abstract No. 192 plus Poster]. Journal of Clinical Oncology, 36, 192.
|
|
[37]
|
Kelly, K., Infante, J.R., Taylor, M.H., et al. (2018) Safety Profile of Avelumab in Patients with Advanced Solid Tumors: A Pooled Analysis of Data from the Phase 1 JAVELIN Solid Tumor and Phase 2 JAVELIN Merkel200 Clinical Trials. Cancer, 124, 2010-2017. [Google Scholar] [CrossRef] [PubMed]
|